DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Performance

DRRX opened at $0.82 on Tuesday. DURECT has a twelve month low of $0.62 and a twelve month high of $1.88. The firm’s fifty day moving average is $0.93 and its two-hundred day moving average is $1.23. The firm has a market cap of $25.45 million, a PE ratio of -1.34 and a beta of 0.94.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DURECT stock. Richmond Brothers Inc. increased its stake in shares of DURECT Co. (NASDAQ:DRRX) by 39.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,072,014 shares of the specialty pharmaceutical company’s stock after acquiring an additional 303,670 shares during the period. DURECT comprises about 2.7% of Richmond Brothers Inc.’s portfolio, making the stock its 7th largest position. Richmond Brothers Inc. owned about 3.45% of DURECT worth $1,383,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.